G-CSF/Filgrastim

PreclinicalProtein / enzyme

AAlberta Health services

G-CSF/Filgrastim is one of 8 small molecule programs targeting Transplant Recipient. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transplant RecipientCompleted

Transplant RecipientPreclinical

Completed

Competition

Competitive Landscape

8 competitors in Transplant Recipient

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Approved

1 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 3

Adrucil

EElorac, Inc.

Phase 2

1 4

Sorilux

LEO Pharma

Phase 2

1 5

Letermovir Pill

TThe First Affiliated Hospital of Soochow University

Phase 2

1 6

Myfortic

Novartis

Preclinical

1 7

Bradykinin

VVanderbilt University

Preclinical

2 8

G-CSF/Filgrastim

AAlberta Health services

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplant Recipient1 trial

ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

Completed·AAlberta Health services·N/A·NCT00168168·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for G-CSF/Filgrastim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — G-CSF/Filgrastim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for G-CSF/Filgrastim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alberta Health services company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: AAlberta Health services

G-CSF/Filgrastim

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplant Recipient1 trial

References

Drug Info

Quick Facts

Related News